Tags

Type your tag names separated by a space and hit enter

Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype.
Breast Cancer Res Treat. 2011 Nov; 130(2):499-505.BC

Abstract

Young breast cancer patients are more likely than old patients to experience ipsilateral breast tumor recurrence (IBTR) after breast conserving surgery (BCS). However, the pathological processes underlying this relationship have not been elucidated. We investigated the effect of young age on IBTR in a Korean cohort of women with different molecular subtypes of breast cancer. We analyzed data of 2,102 consecutive breast cancer patients who underwent BCS and post-surgical radiation therapy (RT) at two Korean institutions between 2000 and 2005. Patients were classified as young (≤ 40 years; N = 513) or old (> 40 years; N = 1,589). Breast cancer subtype was determined by estrogen receptor (ER), progesterone receptor (PR), and HER2. Median follow-up duration was 61 months. The 5-year IBTR rate was 3.4% in young patients and 1.1% in old patients (P < 0.001). Univariate analysis indicated that IBTR rate in young patients with luminal A and HER2 subtypes was significantly greater than in old patients with these subtypes (P = 0.015 and P < 0.001, respectively). Multivariate analysis, which used luminal A subtype in old patients as reference, indicated that HER2 subtype in young patients was associated with increased risk of IBTR (hazard ratio, HR = 12.24; 95% CI: 2.54-57.96). Among old patients, HER2 subtype was not associated with increased IBTR. In conclusion, young women had a higher rate of IBTR after BCS and RT than old women. This difference is mainly among women with HER2 subtype. Aggressive local control and adjuvant therapy should be considered for young women with HER2 subtype breast cancer.

Authors+Show Affiliations

Department of Surgery, College of Medicine, Asan Medical Center, 388 Pungnap-dong, Songpa-gu, Seoul 137-737, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21853352

Citation

Kim, Hee Jeong, et al. "Young Age Is Associated With Ipsilateral Breast Tumor Recurrence After Breast Conserving Surgery and Radiation Therapy in Patients With HER2-positive/ER-negative Subtype." Breast Cancer Research and Treatment, vol. 130, no. 2, 2011, pp. 499-505.
Kim HJ, Han W, Yi OV, et al. Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype. Breast Cancer Res Treat. 2011;130(2):499-505.
Kim, H. J., Han, W., Yi, O. V., Shin, H. C., Ahn, S. K., Koh, B. S., Moon, H. G., You, J. H., Son, B. H., Ahn, S. H., & Noh, D. Y. (2011). Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype. Breast Cancer Research and Treatment, 130(2), 499-505. https://doi.org/10.1007/s10549-011-1736-3
Kim HJ, et al. Young Age Is Associated With Ipsilateral Breast Tumor Recurrence After Breast Conserving Surgery and Radiation Therapy in Patients With HER2-positive/ER-negative Subtype. Breast Cancer Res Treat. 2011;130(2):499-505. PubMed PMID: 21853352.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype. AU - Kim,Hee Jeong, AU - Han,Wonshik, AU - Yi,On Vox, AU - Shin,Hee Chul, AU - Ahn,Soo-Kyung, AU - Koh,Beom Seok, AU - Moon,Hyeong-Gon, AU - You,Jong Han, AU - Son,Byung Ho, AU - Ahn,Sei Hyun, AU - Noh,Dong-Young, Y1 - 2011/08/19/ PY - 2011/07/25/received PY - 2011/08/09/accepted PY - 2011/8/20/entrez PY - 2011/8/20/pubmed PY - 2012/2/9/medline SP - 499 EP - 505 JF - Breast cancer research and treatment JO - Breast Cancer Res Treat VL - 130 IS - 2 N2 - Young breast cancer patients are more likely than old patients to experience ipsilateral breast tumor recurrence (IBTR) after breast conserving surgery (BCS). However, the pathological processes underlying this relationship have not been elucidated. We investigated the effect of young age on IBTR in a Korean cohort of women with different molecular subtypes of breast cancer. We analyzed data of 2,102 consecutive breast cancer patients who underwent BCS and post-surgical radiation therapy (RT) at two Korean institutions between 2000 and 2005. Patients were classified as young (≤ 40 years; N = 513) or old (> 40 years; N = 1,589). Breast cancer subtype was determined by estrogen receptor (ER), progesterone receptor (PR), and HER2. Median follow-up duration was 61 months. The 5-year IBTR rate was 3.4% in young patients and 1.1% in old patients (P < 0.001). Univariate analysis indicated that IBTR rate in young patients with luminal A and HER2 subtypes was significantly greater than in old patients with these subtypes (P = 0.015 and P < 0.001, respectively). Multivariate analysis, which used luminal A subtype in old patients as reference, indicated that HER2 subtype in young patients was associated with increased risk of IBTR (hazard ratio, HR = 12.24; 95% CI: 2.54-57.96). Among old patients, HER2 subtype was not associated with increased IBTR. In conclusion, young women had a higher rate of IBTR after BCS and RT than old women. This difference is mainly among women with HER2 subtype. Aggressive local control and adjuvant therapy should be considered for young women with HER2 subtype breast cancer. SN - 1573-7217 UR - https://www.unboundmedicine.com/medline/citation/21853352/Young_age_is_associated_with_ipsilateral_breast_tumor_recurrence_after_breast_conserving_surgery_and_radiation_therapy_in_patients_with_HER2_positive/ER_negative_subtype_ L2 - https://doi.org/10.1007/s10549-011-1736-3 DB - PRIME DP - Unbound Medicine ER -